UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037499
Receipt number R000042692
Scientific Title Comparative study of two types of insulin injector needle Randomized single-group trial
Date of disclosure of the study information 2019/07/26
Last modified on 2019/08/30 08:12:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparative study of two types of insulin injector needle

Acronym

Comparative study of two types of insulin injector needle
Randomized single-group trial

Scientific Title

Comparative study of two types of insulin injector needle
Randomized single-group trial

Scientific Title:Acronym

Comparison Study of Insulin Pen Needles

Region

Japan


Condition

Condition

Diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1


BD Micro Fine Pro 32Gx4mm and Nanopass Needle II 34Gx4mm
To compare the usability of a pen-type insulin injector in clinical use.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Taste of needle which we want to use from now on

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

The subject uses two types of needles.
Nanopass Needle II 34G x 4 mm -> Micro Fine Pro 32 G x 4 mm
Conduct a questionnaire after use.

Interventions/Control_2

The subject uses two types of needles.
Micro Fine Pro 32G x 4 mm -> Nanopass Needle II 34 G x 4 mm
Conduct a questionnaire after use.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

* Patients with type 1 or 2 diabetes.
* Those who are using a pen-type insulin injector to inject insulin.
* Those who are willing to complete all test procedures.
* Those that can enter the results on the test survey form.
* Those who understand the contents of informed consent and are willing to participate in this exam.

Key exclusion criteria

* Pregnancy, or those suspected of it.
* Breastfeeding.
* Those with severe neurological disease.
* Those in physical condition who can not carry out the test procedure (such as patients who can not inject themselves).
* Those judged by the responsible doctor or his / her doctor that there is a risk for participation in this study.
* Patients who have the potential to be confused in the interpretation of test results. Or what I had.
* Employees of pharmaceutical companies or medical equipment companies

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Mizuho
Middle name
Last name Yamabe

Organization

Murakami Memorial Hospital

Division name

Department of Diabetes Internal medicine

Zip code

722-0014

Address

1-14-26,shinhama,Onomichi-city, Hiroshima,722-0014,Japan

TEL

0848-22-3131

Email

mk-hp2@able.ocn.ne.jp


Public contact

Name of contact person

1st name Youko
Middle name
Last name Ochi

Organization

Murakami Memorial Hospital

Division name

Pharmaceutical department

Zip code

722-0014

Address

1-14-26,shinhama,Onomichi-city, Hiroshima,722-0014,Japan

TEL

0848-22-3131

Homepage URL


Email

mkk-pharma@murakami-kinen-hp.jp


Sponsor or person

Institute

Murakami Memorial Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Murakami Memorial Hospital

Address

1-14-26,shinhama,Onomichi-city, Hiroshima,722-0014,Japan

Tel

0848-22-3131

Email

mkk-pharma@murakami-kinen-hp.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 07 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2019 Year 07 Month 01 Day

Date of IRB

2019 Year 08 Month 01 Day

Anticipated trial start date

2019 Year 08 Month 01 Day

Last follow-up date

2019 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 07 Month 26 Day

Last modified on

2019 Year 08 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042692


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name